health economics and outcomes research

A recent study confirmed the most cost-effective treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.
An early palliative care consultation may relieve financial burden up to 28% for patients with advanced cancer.
Duke Cancer Institute has developed a community health program focused on minimizing cancer disparities and improving overall health.
Previously-treated patients with stage IV NSCLC are less likely to utilize palliative care or hospice services compared with those who receive no prior oncologic treatment.

The International Myeloma Foundation (IMF)–the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward a cure–has issued a statement calling a report by the Institute for Clinical and Economic Review (ICER) on the value of myeloma drugs overly simplistic and one that could limit patient access to optimal treatments.

More than 23% of patients with breast cancer who undergo breast-conserving surgery followed by subsequent surgery do not receive the full benefits of surgery due to added costs and complications.
Researchers compared the relationship between randomized controlled clinical trial efficacy data and real-world effectiveness for oncology therapies.
Adherence to distress screening protocols could lead to 18% fewer ER visits and 19% fewer hospitalizations.